BridgeMD
Continuing ovulation induction with letrozole versus switching to gonadotropins in women with polycystic ovary syndrome (MOVIN-II study)
EU CTIS ID: 2024-519354-36-00
What this study is testing
To determine the clinical efficacy of continuing ovulation induction with letrozole versus switching to ovarian stimulation with gonadotropins, in terms of cumulative live birth rate improvement
- Therapeutic use (Phase IV)
A plain-language read of the study's public EU CTIS listing. The study team confirms the details.
Who can take part
You may be able to join if
- Couples or single women with childwish
- Diagnosed PCOS (normogonadotropic anovulation with hyperandrogenaemia (diagnosed clinically by the presence of excessive acne, androgenic alopecia, or hirsutism or by elevated serum levels of total, bioavailable, or free testosterone or dehydroepiandrosterone sulfate) or polycystic ovaries on ultrasound)
- Age 18-42 years
- Ovulatory for six cycles on letrozole treatment
You likely can't join if
- Contra-indication to letrozole
- Total motile sperm count (VCM) < 3 million
- Known bilateral fallopian tube pathology or occlusion (patients with at least one patent fallopian tube are eligible)
- Major medical morbidity (e.g. poorly controlled Type I or Type II diabetes, known liver disease or dysfunction based on serum liver enzyme testing, renal disease or abnormal serum renal function)
- Inability to give informed consent
- Additional contra-indications reported in the SPC are: Hypersensitivity to the active substance, during pregnancy and breast feeding
The study team makes the final eligibility decision.
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling female, 18-64 years. The study team makes the final eligibility decision.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from EU CTIS; the study team decides eligibility.